|March 7, 2013|
|11:51 EDT||ALXN, FFIV||Stocks with call strike movement; FFIV ALXN|
F5 Networks (FFIV) April 110 call option implied volatility decreased 2% to 32, Alexion (ALXN) May 110 call option implied volatility increased 2% to 31 according to iVolatility.
News For FFIV;ALXN From The Last 14 Days
|October 2, 2015|
|15:14 EDT||FFIV||As many as 4.6M Scottrade users' data exposed in breach, KrebsonSecurity says|
Subscribe for More Information
|11:18 EDT||ALXN||Morgan Stanley downgrades select pharma stocks amid drug price scrutiny|
Morgan Stanley downgraded several stocks in the pharmaceutical sector, dropping drugmakers Valeant (VRX), Gilead (GILD) and Regeneron (REGN) to Equal Weight from Overweight. The firm also downgraded specialty pharmacy Diplomat Pharmacy (DPLO) to Equal Weight and cut its rating on drug distributor AmerisourceBergen (ABC) to Underweight, the firm's equivalent of a sell rating. WHAT'S NEW: Democrats' scrutiny of high drug prices may continue, warned Morgan Stanley analyst David Risinger. As a result, it is hard to predict when Valeant, which generated 14% of its Q2 sales rise from price increases, will see its P/E multiple rise, Risinger believes. The company's lower multiple will hinder its ability to conduct M&A and swap or issue equity, according to Risinger, who set a $200 price target on the stock. Morgan Stanley analyst Matthew Harrison downgraded Gilead, noting that U.S. hepatitis C volume growth has dropped in the last few months. Although Harrison thinks that the U.S. hepatitis C market is still strong, he believes that the data could cause the Street to become concerned about Gilead's fourth quarter and 2016 outlook. He set a $127 price target on the shares. Harrison also downgraded Regeneron, stating his belief that two other drug makers, Alexion (ALXN) and Vertex (VRTX), have stronger near-term appreciation potential. He added that Regeneron has a number of potential negative catalysts, including drug pricing concerns and his belief, based on physician feedback, that the launch of the company's cholesterol drug, Praluent, could miss expectations. He set a $593 price target on the shares. AmerisourceBergen, which provides pharmaceutical sourcing and distribution service to healthcare providers, is the most levered to branded price inflation and that attribute could weigh on the shares, said Risinger, who cut his price target to $93 from $120 on the stock. The uncertain outlook for drug prices could keep the stock range-bound, added the analyst. PRICE ACTION: In morning trading, Valeant dropped 2.3% to $175.50, Gilead declined 1% to $97.26, Regeneron was flat near to $472 per share and AmerisourceBergen slid 1.3% to $93.25.
|10:00 EDT||ALXN||On The Fly: Analyst Upgrade Summary |
Today's noteworthy upgrades include: Alexion (ALXN) upgraded to Overweight from Equal Weight at Morgan Stanley... BlackRock (BLK) upgraded to Buy from Neutral at UBS... Dunkin' Brands (DNKN) upgraded to Outperform from Underperform at CLSA... EnPro (NPO) upgraded to Buy from Neutral at Sidoti... Finish Line (FINL) upgraded to Neutral from Sell at Goldman... FutureFuel (FF) upgraded to Buy from Neutral at Roth Capital... Google (GOOG) upgraded to Outperform from Perform at Oppenheimer... Johnson Controls (JCI) upgraded to Buy from Neutral at Nomura... Kennametal (KMT) upgraded to Neutral from Underperform at BofA/Merrill... Lufthansa (DLAKY) upgraded to Buy from Hold at HSBC... Martin Marietta (MLM) upgraded to Buy from Neutral at Longbow... Northern Trust (NTRS) upgraded to Neutral from Sell at UBS... PMC-Sierra (PMCS) upgraded to Positive from Neutral at Susquehanna... Pfizer (PFE) upgraded to Overweight from Equal Weight at Morgan Stanley... Realogy (RLGY) upgraded to Buy from Neutral at Citi... Sarepta (SRPT) upgraded to Outperform from Neutral at Wedbush... Summit Materials (SUM) upgraded to Buy from Neutral at Goldman... TreeHouse (THS) upgraded to Buy from Neutral at BofA/Merrill... Vertex (VRTX) upgraded to Overweight from Equal Weight at Morgan Stanley.
|07:06 EDT||ALXN||Alexion upgraded to Overweight from Equal Weight at Morgan Stanley|
Subscribe for More Information
|October 1, 2015|
|08:33 EDT||ALXN||After massive selloff, large biotechs seen leading sector back|
The biotech sector has been among the worst performing groups during the recent stock market volaility, due to broader macroeconomic concerns as well as sector-specific worries about pushback on drug price increases. However, analysts at JPMorgan and Piper Jaffray issued notes defending a leader in the space, Celgene (CELG), and argued that growth in the sector will continue and cannot be ignored by investors for much longer. BUY CELGENE: JPMorgan analyst Cory Kasimov upgraded Celgene to Overweight citing an "increasingly attractive" valuation following the recent pullback in shares. The company is one the "most fundamentally sound biotechs" and shares at current levels are "too compelling to remain on the sidelines," Kasimov tells investors in a research note. The analyst said that not only does Celgene have an "impressive" proprietary pipeline, but he is also confident in the company's ability to identify potentially first-in-class and best-in-class products to partner on or acquire to continue its growth. Kasimov keeps a $152 price target for the stock. HIGH-GROWTH: Piper Jaffray analyst Joshua Schimmer says recent weakness in the biopharma sector has created a "valuation discrepancy" versus non-growth, non-biopharma stocks that he hasn't seen for a number of years. The sector remains in a "prolonged growth cycle" driven by extended product cycles, attractive and improving pipelines and M&A opportunities, Schimmer told investors in a research note titled "Out of The Ashes, A Growth Sector Poised To Fly Higher." The analyst, who expects large-cap biopharma companies to lift the sector out of the recent weakness, listed Celgene, Alexion (ALXN), Amgen (AMGN) and Endo (ENDP) as his preferred growth names. PRICE ACTION: Celgene shares are down more than 8% over the past month, though the stock closed yesterday up $2.79 to $108.13. During September, Alexion declined 9%, Amgen dropped 9%, Endo fell 10% and the iShares NASDAQ Biotechnology Index ETF (IBB) slid more than 11%.
|06:28 EDT||ALXN||Piper sees 'highly compelling' entry points in large cap biopharma|
Piper Jaffray analyst Joshua Schimmer says recent weakness in the biopharma sector has created a "valuation discrepancy" versus non-growth peers that he hasn't seen for a number of years. The sector remains in a "prolonged growth cycle" driven by extended product cycles, attractive and improving pipelines and M&A opportunities, Schimmer tells investors in a research note titled "Out of The Ashes, A Growth Sector Poised To Fly Higher." He expects large-cap biopharma companies to lift the sector out of the recent weakness. His preferred growth names include Celgene (CELG), Alexion (ALXN), Amgen (AMGN) and Endo (ENDP).
|September 30, 2015|
|10:33 EDT||FFIV||Battleground: Analysts agree Barracuda shares 'cheap,' diverge on ratings|
The shares of Barracuda Networks (CUDA) are falling after the company reported lower than expected revenue and provided weaker than expected guidance. Research firms Piper Jaffray and JPMorgan both said that the shares are cheap in the wake of their huge decline today, though Piper downgraded the shares and JPMorgan kept an Overweight rating on the stock. Barracuda provides IT security and storage solutions, primarily for small and medium businesses. WHAT'S NEW: Barracuda last night reported second quarter earnings per share of 10c, versus analysts' consensus estimate of 9c. The company's revenue, however, came in at $78.4M, below the consensus outlook of $78.7M. Moreover, the company lowered its fiscal 2016 EPS guidance to 34c-36c from 36c-41c. Analysts' consensus estimate was 39c. Barrcuda cut its full-year revenue guidance to $320M-$323M, from $325M-$330M. Analysts' consensus estimate was $325M. The company said that its Q2 results were negatively impacted by longer sales cycles in its Europe, Middle East, and Africa region and it warned that it "saw some evidence" of slowing growth in the storage market. It also stated that its gross billings came in below its expectations. ANALYST REACTION: Piper Jaffray analyst Andrew Nowinski responded to Barracuda's results by downgrading the stock to Neutral from Overweight. Although Barracuda blamed its lower than expected billings guidance on weakness in its storage business, its security billings increased only by high single digit percentage levels, the analyst stated. The shares are "cheap," but the valuation is not compelling enough to recommend the stock, contends Nowinski, who cut his price target for shares to $20 from $40. Barracuda was also downgraded at Macquarie and at Stephens this morning.Conversely, JPMorgan analyst Sterling Auty called Barracuda shares "too cheap to ignore." The company lowered its billings guidance partly due to worries about slowing storage market growth, as indicated by an industry report released last quarter, said Auty. However, the growth of Barracuda's storage business actually accelerated last quarter, reaching about 25%, the analyst stated. He believes that Barracuda's new guidance reflects the company's efforts to be "prudent." Auty cut his price target on the name to $30 from $42 but kept an Overweight rating on the shares. OTHERS TO WATCH: Other publicly traded companies in the IT security space include Check Point (CHKP), F5 Networks (FFIV), FireEye (FEYE), Fortinet (FTNT), Imperva (IMPV), Palo Alto (PANW), Proofpoint (PFPT), Qualys (QLYS) and Symantec (SYMC). PRICE ACTION: In early trading, Barracuda tumbled 33% to $15.90.
|September 29, 2015|
|11:19 EDT||FFIV||Analyst rolls out coverage of IT security stocks with mixed view|
Research firm Stifel initiated coverage of IT security company Barracuda Networks (CUDA) with a Buy rating and started coverage of another company in the sector, Imperva (IMPV), with a Hold rating in notes to investors this morning. WHAT'S NEW: Barracuda is "an emerging leader" in the small and medium business security and storage sectors and it's poised to replace legacy systems in those markets, Stifel analyst Gur Talpaz wrote. The lower than expected billings reported by the company for the first quarter was "an aberration," according to Talpaz, who predicts its billings growth should accelerate in Q2. Unlike legacy threat management systems, Barracuda's products can be bought individually, on an "as needed" basis, by small and medium businesses, Talpaz explained. More importantly, Barracuda's products allow a single administrator to view the majority of the company's security infrastructure from any location, Talpaz noted. Additionally, Barracuda's storage solutions can be implemented using appliance, cloud or hybrid systems, according to Talpaz, who set a $36 price target on the shares. Imperva is "the clear leader" in the small but fast growing Web Application Firewall, or WAF, market, the analyst stated. However, many companies still don't view WAF systems as necessary, reasoning that they do not have that many Web applications, according to Talpaz. Moreover, competition in the market is intense, as network vendors such as F5 Networks (FFIV) and cloud vendors such as Akamai (AKAM) are competing in the relatively small space, the analyst stated. Talpaz expects Imperva to report strong Q3 results, but heading into 2016, he believes that the company's future profitability is "limited,"while its competitive end markets will create challenges and its valuation leaves little room for error. WHAT'S NOTABLE: Talpaz also initiated coverage of another company in the sector, Qualys (QLYS), with a Hold rating. PRICE ACTION: In late morning trading, Barracuda slipped 1.2% to $24.33, Imperva dropped 3.6% to $63 and Qualys advanced 0.4% to $28.59.
|September 25, 2015|
|10:00 EDT||FFIV||On The Fly: Analyst Downgrade Summary|
Today's noteworthy downgrades include: Atlas Air (AAWW) downgraded to In-Line from Outperform at Imperial Capital... Caterpillar (CAT) downgraded to Market Perform from Outperform at William Blair... Cummins (CMI) downgraded to Market Perform from Outperform at William Blair... Emerge Energy (EMES) downgraded after guidance withdrawal at Stifel... Exxon Mobil (XOM) downgraded to Underperform from Peer Perform at Wolfe Research... F5 Networks (FFIV) downgraded to Market Perform from Outperform at Raymond James... Internap (INAP) downgraded on earnings miss, negative outlook at Oppenheimer... Semtech (SMTC) downgraded to Neutral from Buy at MKM Partners... Silicon Laboratories (SLAB) downgraded to Neutral from Buy at MKM Partners... Superconductor Technologies (SCON) downgraded to Neutral from Buy at Ladenburg... Virgin America (VA) downgraded to Market Perform from Outperform at Cowen.
|07:01 EDT||FFIV||F5 Networks downgraded to Market Perform from Outperform at Raymond James|
Subscribe for More Information
|September 24, 2015|
|07:24 EDT||ALXN||Alexion weakness creates buying opporutnity, says Oppenheimer|
Oppenheimer expects Alexion to report better than expected revenue over the next 12-18 months, driven by the launches of its Strensiq and Kanuma drugs. The firm thinks that the drug launches carry little risk, and it does not expect the company to be affected by pricing pressures. It keeps a $228 price target and Outperform rating on the shares.
|September 23, 2015|
|12:36 EDT||FFIV||Government cyber attack affects larger number of fingerprint data |
Subscribe for More Information
|September 22, 2015|
|10:01 EDT||FFIV||On The Fly: Analyst Downgrade Summary|
Today's noteworthy downgrades include: ABB (ABB) downgraded to Underweight from Neutral at JPMorgan... Aaron's (AAN) downgraded to Market Perform from Outperform at Raymond James... Allison Transmission (ALSN) downgraded to Hold from Buy at Deutsche Bank... Anglo American (AAUKY) downgraded to Neutral from Outperform at Credit Suisse... Antofagasta (ANFGY) downgraded to Underperform from Neutral at Credit Suisse... Atmel (ATML) downgraded to Hold from Buy at Needham... Cummins (CMI) downgraded to Hold from Buy at Deutsche Bank... DuPont Fabros (DFT) downgraded to Sector Perform at RBC Capital... F5 Networks (FFIV) downgraded to Neutral from Buy at Guggenheim... Horizon Pharma (HZNP) downgraded to Hold from Buy at Brean Capital... Infoblox (BLOX) downgraded to Hold from Buy at Deutsche Bank... Israel Chemicals (ICL) downgraded to Sell from Neutral at Goldman... NetApp (NTAP) downgraded to Sell from Neutral at Goldman... Nimble Storage (NMBL) downgraded to Neutral from Buy at Goldman... Oxford Instruments (OXINF) downgraded to Underperform from Hold at Jefferies... Societe Generale (SCGLY) downgraded to Neutral from Overweight at JPMorgan... Toronto-Dominion (TD) downgraded to Neutral from Outperform at Credit Suisse... Virgin America (VA) downgraded to Market Perform from Outperform at Raymond James.
|07:30 EDT||FFIV||F5 Networks downgraded to Neutral from Buy at Guggenheim|
Subscribe for More Information